Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In rats with cyclophosphamide-induced hair loss, this study found that applying cetirizine HCl-loaded emulgel with microneedling stimulated hair growth, suggesting a potentially safer alternative to minoxidil for treating chemotherapy-induced alopecia.

This case report describes a 45-year-old woman who developed Cushing's syndrome and hirsutism after using topically applied desoximetasone (Topicorte).

This review discusses current anti-inflammatory treatment options for calcium pyrophosphate crystal deposition disease (CPPD) and highlights the lack of crystal-targeted therapies, emphasizing the need for more research to guide treatment.

This study reported that high-dose mizoribin therapy may be effective and safe for managing steroid-dependent pediatric systemic lupus erythematosus but requires monitoring of serum uric acid levels due to potential side effects.

This study found that the progesterone metabolite 3α-THP increased the proliferation and gene expression of human glioblastoma cells, suggesting a role in tumor progression.

This study found that the oral IRAK4-inhibitors BAY 1834845 and BAY 1830839 reduced skin inflammation and systemic inflammatory responses in healthy volunteers, showing similar pharmacodynamic effects to prednisolone when challenged with topical imiquimod and intravenous LPS.

In this study of 40 dermatomyositis patients, most with moderate-severe disease at baseline improved over time in a polyphasic pattern, while those with mild disease often remained stable.

In 2002, various drugs caused serious side effects, including vitamin B12 deficiency, heart issues, blindness, hypersexuality, allergic reactions, blood clotting problems, pupil dilation, capillary leak syndrome, muscle breakdown, hepatitis, skin reactions, and lupus.

Cyproterone acetate therapy improved hair loss and reduced testosterone levels in a menopausal woman.

This study found that both combined therapy with goserelin and oral contraceptives, and oral contraceptives alone, significantly reduced hair diameter in severe hirsutism without a significant difference between treatments.

This abstract lists keywords related to various medications and therapies, but it does not provide new study results or findings.

This report describes two renal transplant patients whose hair loss improved after switching from tacrolimus to cyclosporine, suggesting that cyclosporine might counteract steroid-induced alopecia.

This study found that manipulating maternal cortisol levels during pregnancy altered Merino sheep wool characteristics, increasing fibre length and reducing crimp frequency in the offspring.

Progesterone treatment improved seizures in a woman with menstrual cycle-related epilepsy, but a wrong medication worsened her condition.

This study found that novel MPC inhibitor analogues with specific chemical modifications promoted significant hair growth in shaved mice when applied topically.

This study is investigating the efficacy and safety of proxalutamide, an androgen receptor antagonist, in treating severe or critically ill patients with COVID-19, aiming to provide new insights into potential therapeutic options. Results are not reported yet.

This case report describes a 52-year-old woman who developed retiform purpura after using cocaine likely adulterated with levamisole, highlighting the need for levamisole detection in such cases.

This study found that a chemotherapy regimen combining CMFVP and ACP treatments for unresectable metastatic breast cancer yielded a 66.7% overall response rate, with premenopausal women responding more favorably than postmenopausal women.

This study found that some synthesized 17-oximino-5-androsten-3β-yl esters demonstrated stronger cytotoxicity and antiandrogenic activity against prostate cancer cells than finasteride.

Minoxidil works better for female hair loss, but cyproterone reduces scalp oiliness and causes menstrual issues.

This systematic review assessed cyclosporine's effectiveness with or without corticosteroids for treating alopecia areata, finding combined therapy more effective and with a lower recurrence rate than monotherapy, especially for severe cases, though results varied by alopecia type.

In this study, rituximab treatment for children with steroid-dependent nephrotic syndrome was associated with a longer remission time and fewer side effects compared to cyclophosphamide.

This study reports a unique case of coinheritance of BRCA2 and CYLD pathogenic variants in a man with metastatic malignant cylindroma, suggesting that recognizing such genetic profiles in rare conditions can provide new treatment options, including the potential use of therapies targeting BRCA deficiency.

This study found that while some patients with severe alopecia areata responded to high-dose prednisolone, the response was inconsistent and the therapy's risks prevent recommending it for general use.

In this study, researchers found that topical application of 3-β-methoxy-Δ18-oleanene (miliacin) in mice sped up the recovery of hair follicles damaged by cyclophosphamide, moving them into a new hair growth cycle more quickly compared to controls.

This case report discusses an atypical presentation of bullous pemphigoid in a young man potentially triggered by occupational chemical exposure, highlighting diagnostic challenges and effective treatment with clobetasol propionate and prednisolone, transitioning to mycophenolate mofetil.

Bicalutamide mesotherapy improved hair density in women with hair loss and was well received.

This study found that corticosteroid pulse therapy may be more effective than oral cyclosporine with corticosteroid for patients with severe alopecia areata, especially for those with the plurifocal type or a short disease duration.

This study found that oral contraceptive pills containing cyproterone acetate and drospirenone were more effective at reducing hirsutism in women with PCOS than those containing levonorgestrel over a 6-month period.

This phase 1 study reported that after administering supratherapeutic doses of cortexolone 17α‐propionate, a topical antiandrogen intended for hair loss treatment, there was no effect on the QTc interval, indicating no measurable cardiac safety concerns in the concentration range tested.